Cardiovascular Side Effects Common With Proteasome Inhibitors in Multiple Myeloma
Cardiovascular adverse events were more common with carfilzomib therapy and within the first 3 months of treatment.
Multiple Myeloma
Cost Burden of Disease Progression High in Multiple Myeloma
For patients receiving drug therapy, economic burden substantial across lines of therapy
Unacceptable Benefit-to-Risk Ratio for Addition of Pembrolizumab to 2 Standard-of-Care Regimens in Multiple Myeloma
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
SAVED Tool Improves Assessment of Venous Thromboembolism Risk in Patients With Multiple Myeloma
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Dynamic Progression Risk of MGUS to Multiple Myeloma Supports Annual Monitoring
Progressive MGUS and light-chain MGUS were both associated with skewed serum free light chain ratios.
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Response Rates With Ixazomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Very good partial response or better was seen in nearly two-thirds of patients receiving the triplet treatment.
Improved Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Daratumumab Re-Treatment
Patients who were naive to daratumumab experienced an overall response rate of 91.7%; median progression-free survival in this cohort was not reached.
FDA Approves Novel Therapy for Relapsed, Refractory Multiple Myeloma
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Darzalex Gets Approval for Additional Multiple Myeloma Indication
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
